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First-in-human safety, pharmacokinetics, and preliminary efficacy of
TPX-0022, a novel inhibitor of MET/SRC/CSF1R in patients with
advanced solid tumors harboring genetic alterations in MET
D. Hong1, L. Bazhenova2, B.C. Cho3, S. Sen4, M. Ponz-Sarvise5, R. Heist6,
Z. Zimmerman7, X. Le8, D. Xuan9, Z. Junming10, J. Lee11. 1The University of
Texas MD Anderson Cancer Center, Department of Investigational Cancer
Therapeutics, Houston, USA; 2UC San Diego Moores Cancer Center,
Medical Oncology, San Diego, USA; 3Yonsei Cancer Center- Severance
Hospital, Medicine, Seoul, South Korea; 4Sarah Cannon Research Institute
at HealthONE, Medical Oncology, Denver, USA; 5Clinica Universidad de
Navarra, Medical Oncoloy, Pamplona, Spain; 6Massachusetts General
Hospital, Medicine, Boston, USA; 7Turning Point Therapeutics- Inc., Clinical
Development, San Diego, USA; 8The University of Texas MD Anderson
Cancer Center, Department of Thoracic Head and Neck Medical Oncology,
Houston, USA; 9Turning Point Therapeutics- Inc., Clinical Pharmacology,
San Diego, USA, 10Turning Point Therapeutics- Inc., Biostatistics, San
Diego, USA; 11Samsung Medical Center, Hem/Oncology, Seoul, South
Korea
Background: Oncogenic alterations in MET, including amplifications,
fusions, and activating mutations (kinase domain [KD] or exon 14 [Δex14]),
occur in many tumor types. TPX-0022 is a novel type I tyrosine kinase
inhibitor (TKI) that targets MET, SRC, and CSF1R. SRC family kinases are
key downstream nodes for MET signaling that regulate hepatocyte growth
factor expression which may contribute to MET inhibitor resistance.
Targeting CSF1R modulates tumor associated macrophages which may
contribute to TPX-0022 activity. TPX-0022 has shown activity in multiple
preclinical xenograft models. This phase I study (NCT03993873) is
assessing the maximum tolerated dose (MTD), safety, pharmacokinetics
(PK), and clinical activity of TPX-0022 in patients (pts) with advanced solid
tumors harboring genetic MET alterations.
Patients and methods: Adults with advanced cancers harboring genetic
MET alterations detected by tissue or liquid biopsy were enrolled in a 3+3
dose escalation trial. Expansion was allowed at doses where clinical activity
was observed. Treatment with a prior MET inhibitor was allowed. TPX-0022
was given orally in continuous 28-day cycles.
Results: As of 17 September 2020, 18 pts have been enrolled across 4
doses (20–120 mg QD): non-small cell lung cancer (NSCLC; n = 11),
colorectal cancer (CRC; N = 4) and gastric (GC; n = 3). MET alterations
included amplification (N = 9), Δex14 (n = 7) and fusion (n = 2). Median age
was 63 (44–84). Median number of prior therapies was 3 (1–6). 7/18 (39%)
had received a prior MET inhibitor. The most common adverse events (AEs)
were dizziness (61%), amylase increase (33%), lipase increase (33%),
fatigue (33%), and nausea (33%). There were no grade ≥3 treatment-related
AEs. No events of interstitial lung disease/pneumonitis, grade 3 edema, or
grade 3/4 ALT/AST elevation were reported. MTD was not reached. One
dose limiting toxicity of grade 2 dizziness occurred at 120 mg QD. Systemic
exposure increased in a dose-dependent manner. The steady state trough
concentrations were above the IC95 for inhibition of MET phosphorylation.
Efficacy was assessed by RECIST 1.1 and eleven subjects were efficacy
evaluable. One subject with Δex14 NSCLC achieved a PR. Two subjects
with MET amplified GC achieved a PR and one subject with MET amplified
CRC achieved a PR (unconfirmed).
Conclusions: TPX-0022 is a novel MET/SRC/CSF1R inhibitor. TPX-0022
was generally well-tolerated. Responses were observed in Δex14 NSCLC
and MET amplified GC and CRC. TPX-0022 exposure increased in a dose-
dependent manner and steady state trough concentrations were above the
IC95 for inhibition of MET phosphorylation. Phase 2 studies are planned in pts
with cancers harboring MET alterations.
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Discovery of Covalently-bound, First-in-Class Allosteric Inhibitor of
PRMT5
D. McKinney1, M. Ranaghan1, B. McMillan2, M. Brousseau1, M. O’Keefe1,
J. Moroco1, R. Singh1, B. Besnik1, P. McCarren1, K. Mulvaney3, W. Sellers3,
A. Ianari3. 1The Broad Institute, CDoT, Cambridge, USA; 2Tango
Therapeutics, Biochemistry/Biophysics, Cambridge, USA; 3The Broad
Institute, Cancer Program, Cambridge, USA
MTAP-deleted cancer cells are selectively dependent on the expression of
both the methyltransferase PRMT5 and its substrate adaptor proteins
(SAPs), pICln and Riok1. Inhibition of this interaction represents a possible
therapeutic strategy for MTAP-deleted cancers. We recently elucidated the
molecular basis for the PRMT5-adaptor interaction, which is mediated by a
highly conserved binding motif across SAPs (PRMT5 Binding Motif – or
PBM) and a surface exposed pocket on PRMT5 (PBM groove) (Mulvaney
et al, 2020 BioRxiv). Based on these observations, we conducted a FP-
based HTS against >800 K small molecules to identify compounds that
inhibit the interaction between SAPs via the PBM-groove. This screen led to
the identification of a class of compounds that target this mechanism with a
covalent mode of action. Structure based drug design (x-ray co-crystal and
cryo-EM) allowed for improvement in apparent potency with concomitant
reduction of chemical reactivity. The resulting exemplar BRD0639 represents
a first-in-class PRMT5 covalent allosteric inhibitor that targets this protein-
protein interaction.
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KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/
Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS
G12C Mutation
P.A. Jänne1, I.I. Rybkin2, A.I. Spira3, G.J. Riely4, K.P. Papadopoulos5,
J.K. Sabari6, M.L. Johnson7, R.S. Heist8, L. Bazhenova9, M. Barve10,
J.M. Pacheco11, T.A. Leal12, K. Velastegui13, C. Cornelius13, P. Olson13,
J.G. Christensen13, T. Kheoh13, R.C. Chao13, S.H.I. Ou14. 1Dana Farber
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Institute, Medical Oncology, Detroit, USA; 3Virginia Cancer Specialists, US
Oncology Research, Fairfax, USA; 4Memorial Sloan Kettering Cancer
Center, Weill Cornell Medical College, New York, USA, 5START Center for
Cancer Care, Clinical Research, San Antonio, USA; 6Perlmutter Cancer
Center, New York University Langone Health, New York, USA, 7Sarah
Cannon Research Institute, Tennessee Oncology, Nashville, USA;
8Massachusetts General Hospital, Cancer Center, Boston, USA, 9University
of California San Diego, Moores Cancer Center, San Diego, USA; 10Mary
Crowley Cancer Center, Medical Department, Dallas, USA, 11University of
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USA; 12University of Wisconsin, Carbone Cancer Center, Madison, USA,
13Mirati Therapeutics- Inc., Research & Development, San Diego, USA;
14University of California- Irvine, Chao Family Comprehensive Cancer
Center, Orange, USA
Background: KRAS is a key mediator of a signaling cascade that promotes
cellular growth and proliferation and is themost frequently mutated oncogene
in cancers, including lung adenocarcinoma. Adagrasib, an investigational
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